Compare NCRA & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | AYTU |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Taiwan | United States |
| Employees | 22 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | NCRA | AYTU |
|---|---|---|
| Price | $0.84 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 80.1K | ★ 110.9K |
| Earning Date | 04-01-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,106,275.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.95 |
| 52 Week High | $2.40 | $2.82 |
| Indicator | NCRA | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 74.77 |
| Support Level | $0.78 | $2.42 |
| Resistance Level | $0.93 | $2.59 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 20.43 | 81.21 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.